pCDCAR1 ErbB2 h(28FcγR)(CAR-MZ136)
The vector of anti-ErbB2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human ErbB2. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-ErbB2 antibody linked to CD28 and FcγR signaling domains. And the vector product was designed for the treatment of ErbB2 positive cancers.
Targeting Cell Type
ErbB2 positive cancers
Discription of Signaling Cassetes
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells (APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
Fc-gamma receptors (FcγR) are Fc receptors (abbreviated FcR) for antibody IgG. All of the Fcγ receptors (FcγR) belong to the immunoglobulin superfamily and are the most important Fc receptors for inducing phagocytosis of opsonized (marked) microbes. This family includes several members, FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), FcγRIIIB (CD16b), which differ in their antibody affinities due to their different molecular structure.
Erb-b2 receptor tyrosine kinase 2
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-ErbB2 scFv h(CD28-CD3ζ) CARNK, pCDCAR1
||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/19k, Anti-ERBB2), Viral particle
||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/55k, Anti-ERBB2-5), Viral particle
||Anti-ErbB2 scFv h(CD4-CD3ζ) CARNK, pCDCAR1
||Human anti-Her2 T cell receptor (D1), pCDTCR1
||Anti-ErbB2 (4D5 ) h(CD28-FcγR) CAR, pCDCAR1
||Anti-ErbB2 (N29) h(CD28-CD3ζ) CAR, pCDCAR1
||Lenti-ErbB2 CAR (scFv-b2c-CD3ζ, OTI5C4) Viral Particle
||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ55k, Anti-ERBB2-4), Viral particle
||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ24/19k, Anti-ERBB2-1), Viral particle